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Abstract: Cornea is the transparent layer in front of the eye that does not contain blood vessels.
Among eye diseases, corneal neovascularization (NV) is one of the major causes of vision loss,
since it can also lead to blindness. An herbal extraction containing flavonoid, kaempferol (KA),
with antiangiogenic effect was chosen as a candidate drug for inhibited vessel formation. The use
of nanomedicine has led to higher drug bioavailability and slow release of the drug as an effective
therapeutic formulation in ocular drug delivery. In this study, we prepared gelatin nanoparticles
(GNP) with kaempferol encapsulation (GNP-KA) for corneal NV treatment by topical delivery, i.e.,
eye drops. We found that GNP with/without KA loading was in the size of 85−150 nm, and its
zeta potential was around 22−26 mV. The KA entrapment rate of GNP-KA was around 90−98%,
and the loading rate was about 4.6%. The TEM results clearly indicated the GNP-KA NPs to be
round spheres. The in vitro test involved the adoption of human umbilical vein endothelial cells
(HUVECs) for coculture with these nanoparticles. From WST-8 assay, and cell migration examinations,
it was evident that GNP-KA had the capacity to inhibit the cell viability and function of HUVECs.
The results from in vivo tests such as ocular vessels observation, hematoxylin & eosin (H&E) stain,
and metalloproteinases (MMP)/vascular endothelial growth factor (VEGF) quantification revealed the
mice’s eyes with corneal NV treated by eye drops containing GNP-KA once daily for 7 days had better
therapeutic effects with less vessels in-growths in the cornea, compared to the KA solution group
by reducing the production of MMP and VEGF in the cornea. Therefore, we expected to achieve a
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comfortable treatment with a simple method using nanomedicine (GNP-KA) as ophthalmological
agent delivered as eye drops.
Keywords: gelatin nanoparticles; kaempferol; corneal neovascularization; anti-angiogenesis; human
umbilical vascular endothelial cells (HUVECs)
1. Introduction
Corneal disease is a significant global health problem, with visual scarring accounting for about
5% of the blindness worldwide which approximates to 4.9 million people making it the second most
common cause of blindness after cataract [1–4]. Corneal neovascularization (NV) is usually the
formation of new blood vessels in the cornea which may be associated with physical damage, chemical
burns, microbial infections and inflammation, hypoxia, and limbal barrier function. A continual
worsening of corneal NV may lead to partial or complete blindness [1–3]. Corneal transplantation
is reserved for the blind cases; however, vascularization in the transplanted cornea remains one of
the major risk factors for transplant failure. Corneal NV generally implies to a neovascularization of
the cornea from the edge to the middle, a result of an imbalance between vascular epithelium growth
factor (VEGF) and anti-angiogenic factors like angiostatin and endostatin [2,5]. It also involves the
upregulation of angiogenic factors such as metalloproteinases (MMP) causing a degradation of the
extracellular matrix and the basement membrane leading to the remaining proteolytic enzymes to
enter the space between the epithelium and the corneal stroma[6]. Under such conditions, the corneal
epithelial cells and macrophages produce VEGF and b-Fibroblast growth factor (bFGF) which then enter
the space between the corneal epithelium and the stroma through MMPs and stimulate angiogenesis
in the cornea [2,7].
The traditional pharmaceutics for treating corneal NV is the use of topical steroidal eye drops.
However, the long-term use of steroids increases the risk of infection, cataract and glaucoma [8].
The development of anti-angiogenic therapies such as antibodies against the VEGF receptor
(Bevacizumab (Avastin®) or Aflibercept) has gained some interest in recent years due to its successful
use in the treatment of choroidal and retinal NV [2,9–11]. These agents have been tested in experimental
models and in clinical trials with ocular NV including cornea [9,10,12–14]. The clinical outcome from
topical anti-VEGF agents tend to be variable with risks of complications such as epithelial erosion
and corneal thinning [2,9]. Suppressing VEGF signaling may also have adverse effects on the normal
functioning of the eye, in relation to physiological angiogenesis such as the requirement of VEGF for
the maintenance of subretinal vasculature and cone photoreceptors [11]. While further study is needed
to ensure the suitability of anti-VEGF agents for the treatment of corneal NV, additional or alternative
therapeutic approaches should be explored to improve current treatment options. Besides, an ideal
therapeutic strategy, comprising of less invasive, reduced risk and long-term inhibition of angiogenesis
via lesion targeting is the need of the hour.
As mentioned, many conditions are responsible for corneal NV, therefore, the eyes are usually
not only in an angiogenic but also an inflammatory condition. Only anti-VEGF treatment in case
of corneal NV is not enough. A dual functional drug with anti-angiogenic and anti-inflammatory
capabilities is required for the simultaneous treatment of corneal NV. Flavonoids are one such
group of organic compounds, capable of acting on the various mechanisms and etiological factors
responsible for the development of different sight threatening ocular diseases [15]. Kaempferol
[3,5,7-trihydroxy-2-(4-hydroxyphenyl)-4H-1-benzopyran-4-one], is among one of the most common
dietary flavonoids, recently shown to possess antioxidant and antitumor properties [16]. H. Luo
revealed Kaempferol to be low in cytotoxicity but still possessing the abilities to inhibit angiogenesis
and VEGF expression in human ovarian cancer cells [17]. It was also found to exhibit anti-inflammatory
effects and suppress vascular smooth cell migration [18]. Another flavonoid, (−)-Epigallocatechin
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gallate (EGCG), was revealed to inhibit inflammation in murine dry-eye syndrome [19], and suppress
corneal neovascularization due to its anti-inflammatory and anti-angiogenic effect when targeted on
the ocular surface by topical delivery [20]. The inhibitory effects of Kaempferol in-vitro is through
endothelial cells induced apoptosis [18]. Experiments in zebrafish also concluded that kaempferol
could reduce the expression of VEGFR-2 to inhibit angiogenesis [21]. Up until now, few studies focus
on using Kaempferol for treating abnormal vessel growth in eyes including corneal neovascularization.
Therefore, we think that Kaempferol, a bifunctional agent with anti-angiogenesis & anti-inflammation
effect can be used for ocular neovascularization treatment by topical delivery.
Nowadays, ocular drug delivery faces numerous obstacles that impede adequate drug delivery and
efficacy. Ways to deliver drugs to the ocular region include oral medications by systemic administration,
intravitreal injections, intraocular implants and topical eyedrops [22,23]. Topical delivery of drugs or
other compounds are preferred due to the ease of administration and patient compliance. Eyedrops
are one of the non-invasive and easy to administer ways of topical drug delivery. However, the corneal
and conjunctival epithelia serve as a static barrier to topical instillation of drugs, and have low rates of
diffusion. Bioavailability is limited by the volume that can be held by the human eye (~30 µL) and the
rapid rate of tear turnover (~1 µL/min) [23,24]. Thus, only <5% of an eyedrop–instilled dose is delivered
to anterior sections of the eye due to the elimination of the conjunctiva and nasolacrimal duct [24,25].
High concentration dosage is way to solve the problem of low content, but this method is not accurate
due to a dramatical variation in the therapeutic concentration in the ocular tissues. These limitations
have prompted researchers to develop novel formulations for the treatment of ocular disorders.
Nanomedicine has also found applications in ophthalmology, by providing safer, less invasive,
and cheaper treatment options [26]. Zimmer A et al., stated that a particle size of not more than
10 µm would not act as a foreign body to the eye [27]. The size of nanoparticles should generally lie
between 10–1000 nm for a slow release, less irritation as a foreign substance, and lower frequency
of administration. The major advantage of using nanomedicine for the treatment of ocular diseases
is to achieve targeted drug delivery, controlled release, enhanced bioavailability of topical delivery,
and finally improved therapeutic efficacy for ocular disease treatment [24,26]. Nanoparticles made up
of various biodegradable polymers like chitosan, gelatin, sodium alginate and hyaluronic acid (HA)
can be used effectively for efficient drug delivery to the ocular tissues due to the electrical attraction of
nanoparticles with ocular surface [28–31]. The natamycin (NAT) loaded-nanoparticle consisting of
lecithin and chitosan to enhance the NAT precorneal retention, sustain release, high ocular availability
at reduce dose and dosing frequency were proofed [29]. Tseng et al., prepared positively and negatively
charged gelatin nanoparticles (GNP) with TAMRA-GNP particles and investigated their delivery rates
in rabbit cornea showing that the GNP was successful in extending the residence time of the drug in
the ocular surface [28]. In this study, a natural polymer derived from collagen, gelatin is used as the
raw material to prepare nanoparticles. The main focus of this study is the use of kaempferol loaded in
GNP (GNP-KA) to investigate their therapeutic effect on corneal NV in an alkali burning eye model in
mice. The schematic drawing of this study is revealed in Figure 1.
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Figure 1. The schematic drawing of this study: (a) gelatin nanoparticles with KA loading and its in vitro
test in HUVECs, (b) the nanomedicine was used as eye drop to treat corneal NV via the electrical
attraction between particles and cornea to get good therapeutic effect.
2. Materials and Methods
2.1. Nanoparticle Preparation
The gelatin nanoparticles (GNP) were prepared by a two-step desolvation method as described
previously with some modifications [28,32]. Type A gelatin (bloom 175) was used and purified
by acetone for first desolvation followed by dissolution in hot water at final concentrations of 1%
(weight/volume, w/v) and 2% (w/v). Kaempferol (KA) was subsequently dissolved in DMSO in the
storage concentration of 10 mg/mL separately, and then 50 µL of KA solution was added into the
gelatin solution (1mL). Acetone was added again dropwise to form. Various parameters for prepared
kaempferol (KA) loaded GNP (GNP-KA) were tested including the change of concentration and
pH values of gelatin solution; cross-linked by different concentration of glutaraldehyde, and the
stirring times for the crosslinking reactions were evaluated. After particle preparation, the remaining
organic solvent was evaporated using a rotary evaporator (EYELA, Tokyo, Japan), and the resultant
nanoparticles were stored at 4 ◦C for further examination.
2.2. Characterization of GNP-KA
After the preparation of KA loaded GNPs, the dynamic light scattering analyser (DLS) (ZS90
Plus; Malvern, UK) at 25 ◦C with scattering light at 90 degrees and 180 s was used for measuring
the particle size. The surface charge of nanoparticles was also examined by the DLS in the zeta sizer
mode. The structure and morphology of nanoparticle was conducted through a transmission electron
microscope (TEM, Hitachi HT-7700, Tokyo, Japan) at an acceleration voltage of 75.0 kV. Nanoparticles
(GNP or GNP-KA) were dropped onto carbon coated nickel mesh with post-staining by 0.5% uranium
acetate (UA) for TEM sample preparation. Moreover, the chemical components for each material were
detected by Fourier transform infrared spectroscopy (FT-IR 6200 instrument, Jasco, Tokyo, Japan).
Before testing, the lyophilized nanoparticle powder was mixed with potassium bromide (KBr), then
used in the FTIR examination with the scanning range between 400–4000 cm−1. The KA concentration
was quantified using high performance liquid chromatography (HPLC). A C18 column (ZORBAX,
Eclipse plus-5 µm, Agilent, Santa Clara, CA, USA) and the mobile phase included methanol, acetonitrile,
water and acetic acid in the volume ratio of 40:20:39:1 was used; the flow rate of mobile phase was
1 mL/min. The KA was identified at the 350 nm UV. A series KA concentration from 1–500 µg/mL as
prepared and measured as standard curve. Encapsulation efficiency (EE) is calculated as the final drug
content compared with the initial added drug content; the loading rate (LR) is calculated as the final
drug content in the whole nanomedicine base.
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2.3. In Vitro Test
2.3.1. Cell Viability Test
Human umbilical vascular cells were used in this study. HUVECs were maintained and cultured in
M199 medium with 10% fetal bovine serum (FBS)/1x penicillin-streptomycin-neomycin (PSN) antibiotic
mixture addition, supplemented with endothelia cells growth supplement ECGS (30 µg/mL) and
heparin (25 U/mL). Before HUVECs were seeded, the culture dishes or plates were need to be precoated
with gelatin solution (Type A, B300, 1%) for 30 min. HUVECs (5 × 103 cells per well) were seeded in
a 96 well plate; for the next day, the cells were cocultured with variant formulations including GNP,
KA solution, and GNP-KA at different GNP/KA concentrations. The cell viability teat was proceeded
in three repeat experiments, and there’s 6 wells/per tested group examined for the individual condition.
After incubation for 1 and 3 days at 37 ◦C, the cell viability was examined by using the CCK-8 kit
with WST-8 (2-(2-methoxy-4-nitrophenyl)-3- (4-nitrophenyl)-5- (2,4-disulfophenyl)-2H-tetrazolium)
reduction assay. WST-8 agent with M199 at 10:1 volume ratio was mixed, and added to the culture
solution of a mixed reagent of 110 µL per well, and finally cultured in the incubator for 3 h, then using
a microplate reader (Multiskan GO Microplate Spectrophotometer, Thermo Scientific, Waltham, MA,
USA) tested at 450 nm. The percentage of viable cells was calculated in comparison to control cells,
cultured with medium only.
2.3.2. Cell Migration Test
Angiogenesis not only combines cell growth but is also accompanied by cell migration for cell
growth. HUVECs (2 × 105 cells/well) were seeded into a 24-well plate with 0.1% gelatin pre-coating
and incubated with complete medium at 37 ◦C and 5% CO2 overnight, using a 200-µL tip to scrape
on the cell layer to form a gap between cells. A line of the cell layer was scrapped by using a 200-µL
tip followed by three washes with PBS. Fresh medium containing different formulations including
KA solution, GNP, and GNP-KA at different KA concentration was added to the cells. Three selected
views along the scraped line in each well were photographed by using an inverted microscope ((DMi8,
inverted fluorescence microscope, Leica, Wetzlar, Germany). Cells incubated with fresh medium were
used as control. After 2, 6, 8, and 18 h of incubation, images were captured at 40× magnification.
The average scraped area in each well was measured and the change in the area for each experimental
condition was compared with that of the control. The cell space and distance in different groups were
measured and compared using Image J Quantitative Analysis.
2.4. In Vivo Test
Male mice (C57BL/6J, 8 to 14 weeks old) were used in this study. The experimental procedure was
approved by the Institutional Animal Care and Use Committee (IACUC) of Taipei Medical University
(IACUC approval no. LAC-2015-0328, 1 July 2016).
2.4.1. Retention of Nanoparticles on the Ocular Surface
The fluorescent dye, (5-(6)-carboxytetramethylrhodamine succinimidyl ester (TAMRA), Life
technologies (Eugene, OR, USA) was also loaded into the GNP and GNP-KA nanoparticles for tracing
them in the eyes. C57BL/6 mice were used for live monitoring by an in vivo imaging system (IVIS-200,
Alameda, CA, USA). The mice were anesthetized, and the eye drops with fluorescent NPs were
directly dosed on the eye (5 µL/eye). The TAMRA (dye solution), GNP and GNP-KA as eyedrops
were diluted by saline and adjusted into the same TAMRA concentration for comparison. Mice’s eyes
with fluorescence were photographed, and the subtraction of tissue autofluorescence to reduce the
background noise was adopted to improve sensitivity. The fluorescent intensity compared with the
initial intensity after dosing was compared in different time intervals.
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2.4.2. Corneal NV Mice Model Establishment
Seventy-two mice were used in this study for three repeated animal tests, and the mice number
for each group (normal, PBS, GNP, KA, and GNP-KA) was six respectively. Briefly, the mice were
anesthetized to immobilize them before examination. Next, topical administration of 0.5% Alcaine®
(Alcon, Puurs, Belgium) for local anesthesia was performed, followed by pressing the tip of an
applicator containing silver nitrate/potassium (25%/75%: Grafco, Atlanta, GA, USA) to the center of the
cornea steadily for eight seconds [20,33]. Excess of nitrate was washed by saline solution. Each mouse
was treated for only one burnt eye. The KA solution, GNP or GNP-KA colloidals were diluted in
PBS as eye drops at a final KA concentration of 7.5 µg/mL, and gelatin concentration of 150 µg/mL.
Five microliters of colloidal solution were applied on the mouse eye as eye drops once daily for
seven days. The burn stimulus response and the severity of neovascularization were then assessed in
anesthetized mice by observation under a hand-held portable slit lamp (SL-17, Kowa Company Ltd.,
Torrance, CA, USA). The extent of corneal NV was scored according to the blisters with a score range
of 0–3 corresponding to as follows: 0—no blisters; 1—slight corneal blisters; 2—moderate increase in
the corneal surface blisters; 3—increase in the blister size to the shape of a cone. After a one-week
treatment, mice were sacrificed, the eyeballs were carefully removed and placed in cassettes followed
by soaking in 10% formalin, then embedded in paraffin for sectioning into 5 µm thickness, and staining
by H&E method. The sections were observed by a Slide-based tissue cytometry (Axio Observer Z1,
Tissue Gnostics, Vienna, Austria).
2.4.3. Angiogenetic Factors Examination from Cornea Lysate
Mice cornea were isolated and weighed. Due to the tiny size of mouse cornea, the cornea from
four mice treated in the same group were collected and lysed to get enough amount of protein lysate
for examination. Cornea from two batches of animal test were examined. The total proteins from
these tissues were extracted with tissue protein extraction buffer (Thermo Fisher Scientific, IL, USA).
Bead beater-type homogenizer was operated at 2600 rpm, followed by centrifugation at 10,000 g
for 3 min at 4 ◦C, then the supernatants were collected. Total protein was quantified by Bradford
assay (p010, GeneCopoeia, Rockville, MD, USA). Angiogenesis cytokines (MMP-2, MMP-9 and VEGF)
content in each group were measured by Quantikine® ELISA kit, Mouse VEGF/total MMP-9/MMP-2
Immunoassay (R&D Systems, Inc. Minneapolis, MN, USA) in triplicate. This experiment was
conducted according to manufacturer’s protocol.
2.5. Statistical Analysis
Data (mean ± standard deviation (SD) from 2–3 independent experiments were shown, and
statistical differences between groups were examined by Student’s t-test or one-way analysis of variance
(ANOVA) test using Excel (Microsoft). A probability (p) value ≤ 0.05 is statistically significant.
3. Results and Discussion
3.1. Optimal Parameters for GNP- KA Preparation
Gelatin nanoparticles (GNP) were prepared by a two-step desolvation method as described
previously [32]. The final GNP needed to be cross-linked by glutaraldehyde (GA) for stability and
rigidity. According to our previous study [28], GA at a final concentration of 0.1% and 0.4% for
prepared GNP-KA were tested, the result of which are shown in Table 1. While keeping other operation
parameters fixed (at room temperature, pH 2.5 for 2% (wt./v) gelatin solution; cross-linking with
GA for 16 h overnight); comparing with 0.1% GA, higher GA concentration (0.4%); smaller particles
(148 ± 10 nm vs. 281 ± 16 nm) with similar zeta-potential (around +24 mV) can be prepared. But the
KA encapsulation efficiency (EE) and loading rate (LR) was higher in the 0.4% GA group (96% ± 2%),
therefore, 0.4% GA was chosen for the future tests. Additionally, cross-linking time (1, 3 and 16 h) for
the prepared GNP-KA was also evaluated (Table 2). The longer GA reaction time can synthesize smaller
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sized KA-GNP (90 ± 8 nm) with higher EE (98% ± 1%). Although the size after 3 h (149 ± 10 nm)
was bigger than the one after 16 h., the EE for these two time limits had no difference (96% ± 2% vs.
+98% ± 1%), so we finally chose 3 h as the time for GA cross-linking reaction to prepare GNP-KA for
adequate EE but time saving. Finally, we also liked to increase the KA ratio in nanoparticles; thus,
a lower concentration of gelatin solution (1% (w/v) was tested (Table 3). In the low polymer-based NP,
the KA ratio in nanomedicine can be increased to 4.6% with a smaller size (85 ± 8 nm) but still higher
EE (95%). According to these results, the 1% (w/v) gelatin Type A solution at pH 2.5 with KA addition
to form nanoparticles, then cross-linked with 0.4% (v/v) GA for 3 h was the optimal condition for the
preparation of GNP-KA as a nanomedicine (85 ± 8 nm) with a positive charge (+25.6 ± 2.1 mV) and a
high KA EE (95%± 1%) and LE (4.6% ± 0.1%).
Table 1. Characterization of GNP-KA prepared in variant glutaraldehyde (GA) concentration.
GA Concn. Size (nm) Zeta (mV) PDI EE (%) LR (%)
0.1 (v/v %) 281 ± 16 +21.5 ± 0.5 0.199 ± 0.020 85 ± 10 2.1 ± 0.3
0.4 (v/v %) 148 ± 10 +24.4 ± 1.9 0.203 ± 0.032 96 ± 2 2.4 ± 0.1
2% (w/v) gelatin solution, stirred for 3 h, n = 3.
Table 2. Characterization of GNP-KA prepared in variant GA cross-linking time.
Crosslinking Time Size (nm) Zeta (mV) PDI EE (%) LR (%)
1 h 138 ± 3 +22.8 ± 0.7 0.330 ± 0.032 90 ± 2 2.2 ± 0.1
3 h 149 ± 10 +24.4 ± 1.9 0.203 ± 0.031 96 ± 2 2.4 ± 0.1
16 h 90 ± 8 +21.4 ± 0.1 0.275 ± 0.010 98 ± 1 2.4 ± 0.0
2% (w/v) gelatin solution, 0.4% GA, n = 3.
Table 3. Characterization of GNP-KA prepared in variant gelatin concentration.
Gelatin Concn. Size (nm) Zeta (mV) PDI EE (%) LR (%)
1% (w/v) * 133 ± 15 +26.6 ± 1.4 0.211 ± 0.072 / /
1% (w/v) 85 ± 8 +25.6 ± 2.1 0.306 ± 0.051 95 ± 1 4.6 ± 0.1
2% (w/v) 149 ± 10 +24.4 ± 1.9 0.203 ± 0.030 96 ± 2 2.4 ± 0.1
* GNP (without KA addition), 0.4% GA, stirred for 3 h. n = 3.
3.2. Characterization of GNP-KA by TEM and FT-IR
The synthesized GNP-KA presented as round and distinct particles with a spherical structure
as assessed by TEM (Figure 2a,b), and its size was around 100 nm in a well dispersed condition
showing aggregation, which was comparable to the DLS result. The TEM images of GNP possess
similar structures as GNP-KA (Data not shown). The FT-IR spectra of GNP and GNP-KA are shown
in Figure 2c. Bands at 1557 cm−1 and 1558 cm−1 belonging to the amide bond (CN) of gelatin in
GNP/GNP-KA were observed. In the pattern of GNP- KA, specific bands at 2855 cm−1 and 2926 cm−1
of kaempferol (KA) attributed to the phenolic group (OH) [34]. The KA was successfully loaded
in GNP.
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Figure 3. Cell viability of HUVECs treated with various NP formulations at different KA concentrations
on (a) day 1, and (b) day 3. (concentration shows in: µg/mL) (one-way ANOVA, n = 6; * p < 0.05
compared with control; # p < 0.05 compared with KA at the same KA concentration; ˆ p < 0.05 compared
with GNP at the same gelatin concentration.
The same width of gaps was created by a 200 µL tip on the HUVEC layer in all groups (0 h),
and representative photos were chosen for show in Figure 4a treated by variant KA formula (KA
7.4 µg/mL). For the quantification data, 3 photos from each group were used and the cells ratio in the
gap area were calculated (Figure 4b). Some HUVECs migrated into the gap after 6 h. After 8 h, many
cells already migrated into the gap, the cells in the gap area was 32.8 ± 2.3% in GNP treated one, and
35.3 ± 3.3% gap area was covered with cells in KA group; but the GNP-KA treated one showed less
cells in the gap area, just 12.1 ± 1.0% gap area was covered by HUVECs (Figure 4b). Eighteen hours
later, there seemed no gap in the control, GNP, and KA groups, almost 100% with cells migration into
the gap area. However, the GNP-KA treated group revealed only 15.2 ± 0.5% gap area covered by cells
due to cell migration (* compared with GNP: # compared with KA) showing the long-term effect for
inhibit cell migration in the KA-loaded nanoparticles (GNP-KA)
Pharmaceutics 2019, 11, 635 10 of 17
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3.4. anoparticles Retain on the Ocular Surface
Pictures of the eyes fro ice treated ith variant eye drops ith dye are sho n in Figure 5a,
quantification data is revealed in Figure 5b showing the percentage of fluorescent signal compared
with the initial intensity. After exposure to the eye drops for 5 min, the mice treated with the GNP
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(67.45% ± 0.56%, * p < 0.05 compared with TAMRA) and GNP-KA (72.61% ± 13.43%) exhibited higher
fluorescent content retention on eye than mice treated with the TAMRA solution (42.23% ± 17.25%).
Subsequently, the highest fluorescence intensity was still recorded in the GNP and GNP-KA groups, and
all of the fluorescence intensity in the nano-groups were much higher than the fluorescence intensity
in the TAMRA (dye solution) treated mice after 120 min (Figure 5a). At 120 minus, the fluorescence
intensity was still around 22% in GNP and GNP-KA group which’s around 3 times higher than the
TAMRA treated one (around 6% fluorescence intensity) comparing with the initial dosing intensity.
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The normal mouse eye with smooth and transparent cornea is shown in Figure 6a. Chemical
cauterization results in neovascularization from limbus towards the burn scar, which these newly
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formed capillaries can be obviously seen arising from limbus area and surrounding the burnt white
patch in the PBS and GNP treated eyes. In contrast, fewer and thinner visible vessels were observed in
both KA and GNP-KA groups (Figure 6a), and the cornea of mice in GNP-KA treated group were better
in transparency with the least amount of vessel formation. The amounts of vessel and areas of NV from
these images were quantified and represented as CNV ratio (Figure 6b). Treatment of KA contained eye
drops (KA solution, or GNP-KA) showed a lower NV ratio indicating a better therapeutic condition
for inhibit vessel formation. There is a significant difference between KA (19.1% ± 1.6%) and GNP-KA
(8.7% ± 1.9%) treated groups showing the advantages for using nano-formulation as eye drops for
effectively treating corneal NV by a single dosage per day.
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KA) have a superior therapeutic effect to inhibit vessels formation in damaged cornea. 
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3.7. Variation of Angiogenic Factors in Cornea 
Formation of corneal neovascularization (NV) is closely associated with the accumulation of 
MMP-2 and MMP-9. Normal corneas were used as control. In Figure 8, the MMP-2/MMP-9 
concentration of control group is 11,908 1,623 pg/mL and 2,616  480 pg/mL, and the VEGF content 
is 3.42  0.33 pg/mL. Mice corneas with NV treated by PBS showed higher concentration of MMP-2, 
-9 (29,481  6,245/86 479  18,287 pg/mL, * p < 0.05 compared with control) and VEGF (16.12  4.34 
pg/mL, * p < 0.05). GNP has no effect on vessels formation, with variations in angiogenetic 
Figure 6. Angiogenesis inhibition in alkali burned cornea. Eyes ere treated by variant for ulation
for one time daily for 7 days. (a) Photos were acquired on day 7 in normal cornea, treated by PBS, GNP,
KA and GNP-KA group (b) Ratio of vessels area in the total cornea was counted. (n = 10, mean ± SD).
KA concentration: 7.4 µg/mL, gelatin concentration: 150 µg/mL, * p < 0.05 compared with PBS, # p< 0.05
compared with KA).
3.6. Histological Results
The microstructure of the corneas before and after treatment were examined under microscope.
Representative images of central corneal sections are shown in Figure 7. From the results, it is evident
that there are more vascular tissues with red blood cells observed (red arrows) in the eyes treated
with PBS and GNP. Corneal stromal injuries were also observed, confirmed by the looser structure
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in stroma (Figure 7b,c,d). In the KA group, less blood vessel formation was observed whereas the
GNP-KA group exhibited almost entirely avascular tissue with the corneal stroma similar as the control
(normal) cornea. These results indicate that kaempferol loaded in gelatin nanoparticles (GNP-KA)
have a superior therapeutic effect to inhibit vessels formation in damaged cornea.
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3.7. Variation of Angiogenic Factors in Cornea
Formation of corneal neovascularization (NV) is closely associated with the accumulation of MMP-2
and MMP-9. Normal corneas were used as control. In Figure 8, the MMP-2/MMP-9 concentration of
control group is 11,908 ± 1623 pg/mL and 2616 ± 480 pg/mL, and the VEGF content is 3.42 ± 0.33 pg/mL.
Mice corneas with NV treated by PBS showed higher concentration of MMP-2, -9 (29,481 ± 6245/86,479
± 18,287 pg/mL, * p < 0.05 compared with control) and VEGF (16.12 ± 4.34 pg/mL, * p < 0.05). GNP has
no effect on vessels formation, with variations in angiogenetic concentration having similar tendency
as the one treated with PBS (* p < 0.05). The KA solution can reduce the concentration of MMP-2
(28,367 ± 3698 pg/mL), MMP-9 (36,243 ± 3231 pg/mL, * p < 0.05 compared with control) and VEGF
(9.58 ± 1.09 pg/mL, * p < 0.05), but no significantly difference with PBS (Figure 8b,c). The nano-KA
formula, GNP-KA, can significantly reduce MMP-9 (9386 ± 3946 pg/mL, * p < 0.05/# p < 0.05 compared
with control/PBS) and VEGF (0.45 ± 0.2 pg/mL, * p < 0.05/# p < 0.05/& p < 0.05 compared with
control/PBS/KA) content. The concentration of MMP-2 in GNP-KA group (24,101 ± 8511 pg/mL) was
the lowest one in all treated groups (excluding the normal cornea). The VEGF content in GNP-KA
treated cornea was even lower than the control group (3.42 pg/mL vs. 0.45 pg/mL, Figure 8c). The
GNP-KA contained eye drop can effectively reduce the angiogenetic factors (MMP-2/-9, VEGF) and
subsequently, reduce vessel formation in the cornea.
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Figure 8. Angiogenetic cytokines variation after 7 days treatment by variant eye drops, the concentration
of (a) MMP-2, (b) MMP-9 and (c) VEGF quantification from the cornea lysates. (n = 3, mean ± SD,
* p <0.05 compared with control, # p < 0,05 compared with PBS, & p < 0,05 compared with KA).
Studies had confirmed kaempferol (KA) could inhibit tumor growth, proliferation, and
angiogenesis by decreasing VEGF expression in human ovarian cancer cell lines [17,35,36].
New application of KA in eyes was investigated recently. The retinal pigment epithelium (RPE)
injury plays an important role in the prevention or delaying age-related macular degeneration (AMD),
or diabetic retinopathy etc. The in vitro and in vivo results from Du W’s study revealed that KA
could protect RPE cells from oxidative stress damage [37]. As a result, KA has the potential to treat
retinal degenerative diseases. The results from Lin C’s study revealed that KA could be used for the
treatment of glaucoma due to its anti-inflammatory and anti-oxidative properties. KA can prevent
changes in retina thickness and retinal ganglion cell (RGC) death in I/R mice; and pro-inflammatory
cytokines were also prevented. Therefore, KA attenuated RGC cell death by inflammasomes, thus
leading to a reduction in acute glaucoma [38]. Novel formula of KA such as a nano-form was also
developed. The poly (dl-lactic acid-co-glycolic acid) (PLGA) nanoparticles (NPs) incorporating KA
was studied, and revealed the PLGA-KA NPs had selective toxicity against cancer cells and normal
cells, therefore being eligible to be used as a prevention and treatment agent for ovarian cancers [36].
Moreover, Ilk S et al. used lecithin/chitosan (LC) to prepare KA loaded NPs as an antifungal agent. The
KA was success-fully encapsulated in LC-NPs with an efficiency of 94% and good physicochemical
stability [39]. In this study, the loading rate of KA in gelatin nanoparticles (GNP-KA) was compatible
(95%, Table 3) with the KA loaded LC-NPs. The KA-LC NPs exhibited a significantly inhibition
efficacy (67%) against Fusarium oxysporium after 60 day, exhibiting its slow release capacity. The results
indicated that KA-LC-NP formulation could solve problems related to the solubility and loss of KA
during use and storage [39]. The storage stability of GNP-KA can last for four weeks at 4 ◦C (data
not shown), the slow release capacity of KA from GNPs can also be confirmed by the cell viability
and migration test showing the longer effect for caused cell viability reduced after 3 days (Figure 3)
and migration inhibition lasting for 24 h (Figure 4). From the details above, new application of KA
and variant polymeric based nanoparticles for loading KA were synthesized for application in cancer,
anti-angiogenesis, and antifungal treatment [17,36,37,39,40]. But none of the KA related nanomedicine
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was studied in eye treatment. In this study, we proved that kaempferol loaded in gelatin nanoparticles
(GNP-KA) can effectively inhibit HUVEC cells function in vitro (Figures 3 and 4) and retard vessel
formation in mice cornea (Figures 6–8) via a decrease in the concentration of MMP-2,-9 and VEGF.
4. Conclusions
In conclusion, it was observed through DLS that the size of the nanoparticles carrying the KA
averaged from about 80–150 nm, the zeta potential was about 22–26 mV and the PDI ranged from
0.199 to 0.306. TEM confirmed the morphology of such particles to be round and distinct particulates
with no aggregation. The successful preparation of KA-loaded GNPs was confirmed by FT-IR through
the individual peaks of naphthol phenolic -OH bonded structure from KA. The results obtained from
the third day of the WST-8 cell viability tests for GNP-KA established the significant cytostatic activity
of the successfully prepared NPs by displaying the inhibition of HUVECs cell viability compared to
the KA group. On the other hand, the Live/Dead test, also reiterated the inhibitory activity of the cells.
Cell migration tests exhibited the effective inhibition of cell migration of the HUVECs in GNP-KA
compared to the other groups. The GNP-KA NPs also showed good therapeutic effect based on the
fact that the GNP-KA group could reduce blood vessel growth on the cornea. Also, it was implied
through H&E staining that the GNP-KA group led to a common structure and less vascular tissue
observation on the cornea compared to the other test groups. These results indicated that the GNP-KA
NPs formulation could have significant therapeutic effects against corneal neovascularization and
also exhibit anti-angiogenic effects, thus making it a viable candidate for utilizing as an eye drops for
effective treating cornea neovascularization.
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